W E L C O M E

CANN GLOBAL ANNUAL GENERAL MEETING

31 January 2022





CEO's address

Sholom Feldman





FY21 Financial Performance





Business

Company loss reduced by 41%



Revenue

Primary source of FY21 revenue (\$1.5m) is from health food division sales, a decrease on FY20 with lower export sales to Vietnam.



Health Food Division

The review of the health food division to drive improved profitability as noted in the Q4 FY21 report, will likely see limited revenue growth from the division as changes are implemented.



Cash balance

Healthy cash balance: \$10m as at 30 September 2021.




Profitability

Focus remains on driving a path to profitability.

Key areas of focus









Key divisional highlights



#01 Health Food

- Successful launch of Chia-Soft-Gel Oil capsules
- Development of equine food range
- Review of range to optimise channel marketing spend, improve margins and competitiveness has been carried out.
- New products being developed to meet consumer demand will launch in FY22.



#02 CBD Cultivation & Processing

- Capital light and highly scalable plant funding model introduced
- Initial revenue from plant funding received in Q1FY22
- Cultivating, processing and distributing CBD hemp on behalf of license holders AA Bio and Green Pharma Botanical.



#03 Cosmeceuticals

- Pilot production of premium hemp seed and Australian native ingredients skincare range.
- Range has now launched in Europe and Australia
- Marketing campaign and mass production to commence Q3 FY22.
- Development underway of CBD range extension



#04 Medicine

- Three Canntab products now available to Australian consumers
- Canntab Australian website and marketing campaign were launched Q2 FY22
- Draft protocol written for human clinical trials of the efficacy of the cannabis strain identified in treating MS

Our growth strategy

- The production and distribution of medicinal cannabis and hemp products remains an emerging industry.
- There is a growing acceptance of the safe use of cannabis in medical treatment, but education and awareness remains key to driving demand for these products.
- Legislation for the production, import and export, and use of cannabis and hemp-based products continues to evolve representing significant opportunity for first-movers.
- A focus on health and well-being supports growth in demand for health food products, nutraceuticals and cosmeceuticals.
- Continued attention to innovation and the pursuit of medical advancement through vital research into the safe use of cannabis for patients, has the potential to deliver significant upside for shareholders.



Our strategic priorities for growth



Cost efficient cultivation & production

Cost efficient extraction and manufacturing services for pharmaceutical grade products in Thailand in an ideal growing environment.



Innovation in product development

Innovation in product development to meet growing demand for new products in existing and new sectors.



Strenghthen distribution channels

New strategies to enhance sales and drive brand and range awareness. Enhancing distribution channels in Australia and international markets with a focus on direct to consumer



Leverage global partnerships

Leverage global partnerships to bring new products to market.



Medical advancement through research

Progress protocol for human clinical trial of identified cannabis strain in the treatment of Multiple Sclerosis.

Summary

#1

Cann Global has not been immune to the impacts of the on going challenges presented by the COVID-19 pandemic.

#2

The Health Food division is being revamped to improve profitability, new revenue streams come online in FY22 from CBD plant funding, the Canntab range and cosmeceuticals.

#3

Regulatory changes across the globe reflect the changing attitudes to cannabis and the Company continues to seek to leverage the benefit of these changes.

#4

Education and awareness are key to building product demand and the company is focused on facilitating this through marketing programs to practitioners, research programs and course sponsorship.

#5

Board and management are committed to managing potential risks to the business and safety of staff in the current uncertain environment.

Disclamer

THIS PRESENTATION (AND ANY OTHER DOCUMENTATION "MATERIALS") HAS BEEN PREPARED BY CANN GLOBAL AND CONTAINS GENERAL INFORMATION ABOUT CANN GLOBAL ACTIVITIES. BY ACCEPTING THESE MATERIALS YOU AGREE TO BE BOUND BY THE BELOW TERMS AND CONDITIONS.

Terms & Conditions

This presentation is provided for information purposes only. The information contained in this presentation is not intended to be relied upon as advice to investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Investors should assess their own individual financial circumstances and consider talking to a financial adviser or consultant before making any investment decision. Certain statements in this presentation may constitute forward looking statements. Such statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. While all reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its subsidiaries, or their respective directors, officers, employees, contractors or agents accepts responsibility for any loss or damage resulting from the use of or reliance on the presentation by any person. Past performance is not indicative of future performance and no guarantee of future returns is implied or given. Some of the information in this presentation is based on unaudited financial data which may be subject to change. All values are expressed in Australian currency unless otherwise stated. All intellectual property, proprietary and other rights and interests in this presentation are owned by the Company.]





Level 21, 133 Castlereagh Street, Sydney NSW 2000 +61 2 8379 1832 info@cannglobal.com.au